Targeted Therapy Sac-TMT Could Change The Future Of Endometrial Cancer Treatment
For people whose endometrial cancer returns after treatment, finding another effective option can be difficult.
For people whose endometrial cancer returns after treatment, finding another effective option can be difficult.
Salivary gland cancer is rare, and there are no standard treatments for advanced-stage disease. Recent research supports the use of HER2-targeted therapy for patients with metastat...
Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and sluggish change, are hindering access.
A systematic review and meta-analysis of 25 clinical trials found that MET tyrosine kinase inhibitors achieved a 49 percent objective response rate in MET-altered non-small cell lu...
The development of KRAS inhibitors has ushered in a new era in precision oncology and renewed efforts in therapeutic targeting of p53, the most commonly altered gene in human cance...
Next-generation immunotherapy exploits diverse immune populations to address the challenges that CAR T-cell therapy faces. The post Therapeutic Immune Manipulation appeared first o...
Targeting FOLR1 with an approved antibody-drug conjugate restored anti-tumor immunity and enhanced anti-PD-1 effectiveness in colorectal cancer, overcoming immune evasion in mouse...
CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.
First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...
At the recent AACR Conference on Pancreatic Cancer, Kevan M. Shokat, PhD, FAACR, received the 2026 Stephenson Global Prize for his pioneering discoveries that opened the door to th...
An experimental oral cancer drug that disrupts a key molecular switch inside tumour cells, when paired with an established targeted therapy, has produced durable tumour shrinkage i...
The startup is built around technology it claims can help get after known, but undruggable cancer targets and design particularly selective autoimmune disease treatments.
J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.
A HER2-targeted mRNA lipid nanoparticle vaccine combined with fractionated radiotherapy suppressed tumor growth and reprogrammed the immune microenvironment in a mouse model of HER...
PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor respo...
A real-world retrospective study demonstrates that adding first-line immunotherapy to chemotherapy significantly prolongs median overall survival by 23 months in advanced SMARCA4-d...
Research Conducted at Tennessee Oncology's Greco-Hainsworth Centers for Research Contributes to Study Showing Longer Overall Survival with Next-Generation KRAS G12C Therapy
Theranostics, also called radiotheranostics, combines targeted disease diagnosis and therapy into an integrated medical process for oncology providers. Although the field isn’t new...
Creative Biogene proudly announces the launch of its flagship lentiviral vector-based in vivo CAR-T development services, aimed at revolutionizing cancer treatments through precisi...
GUANGZHOU, China, Oct. 24, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars,...
Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.